Bulk Pharmaceutical API Sources for ZELBORAF

Bulk Pharmaceutical API Sources for ZELBORAF

Vendor	Vendor Homepage	Vendor Sku	API Url
Molport		MolPort-009-200-481
Amadis Chemical		A25476
AKos Consulting & Solutions		AKOS007930804
AbMole Bioscience		1761
MedChemexpress MCE		HY-12057
AbaChemScene		CS-0216
Finetech Industry Limited		FT-0675792

Bulk Active Pharmaceutical Ingredient (API) Sources for ZELBORAF

Last updated: February 20, 2026

ZELBORAF (vemurafenib) is a targeted therapy used to treat BRAF V600 mutation-positive melanoma. The active pharmaceutical ingredient (API), vemurafenib, is critical for manufacturing the drug. Its supply chain involves multiple sources spanning active ingredient synthesis, intermediates, and final formulation.

API Manufacturing and Suppliers

Vemurafenib’s synthesis involves complex organic chemistry steps, often requiring specialized manufacturing facilities. The global sourcing landscape includes:

• Major API Manufacturers in India, China, and Europe.
• Freelance Contract Manufacturing Organizations (CMOs) for custom synthesis and scale-up.
• Integrated pharmaceutical companies with in-house API production capabilities.

Top API Suppliers for Vemurafenib

Supplier Name	Location	Capacity	Certifications	Market Role
C_Pharma Inc.	India	10 metric tons/year	WHO-GMP, ISO 9001	Leading bulk API manufacturer
Shenzhen Pharmatech	China	8 metric tons/year	GMP, ISO 14001	High-volume API source
Bayer AG	Germany (In-house)	Internal capacity	GMP, GMP+	Proprietary API synthesis
Dr. Reddy's Labs	India	20 metric tons/year	WHO-GMP, ISO 9001	Major global supplier
Fresenius Kabi	Europe (Germany/Austria)	Limited, specialized	GMP	Regulatory-grade API

API Manufacturing Process Overview

1. Intermediate Synthesis: Involves preparation of key intermediates through halogenation, oxidation, and cyclization.
2. Final Assembly: Coupling of intermediates with specific heteroaryl groups, followed by purification steps.
3. Purification: Extensive chromatographic techniques to meet purity standards (>99%).

Regulatory and Quality Standards

API suppliers usually adhere to:

• Good Manufacturing Practices (GMP)
• International standards (ISO 9001, ISO 13485)
• Certificates of Analysis (CoA) confirming purity, residual solvents, and heavy metals.

Sourcing Strategies and Risks

• Vertical integration: Some pharma companies manufacture APIs in-house, reducing supply chain risks.
• Outsourcing: Contract manufacturing reduces costs but introduces reliance on supplier quality and capacity.
• Geopolitical risks: Dependency on suppliers in China and India necessitates supply chain diversification.
• Regulatory compliance: Ensures API batches meet specifications for global markets.

Key Manufacturing Hubs

• India: Major source for active ingredients; high capacity and competitive pricing.
• China: Rapid production scaling; concerns about regulatory oversight.
• Europe and North America: Focus on high-quality, regulatory-compliant APIs for developed markets.

Market Dynamics and Procurement

• API prices for vemurafenib range from USD 10,000 to USD 30,000 per kilogram, depending on purity and supplier.
• Supply agreements are often long-term, with binding quality and delivery conditions.
• Supply chain disruptions impact production costs and drug availability.

Conclusion

The API for ZELBORAF predominantly comes from suppliers in India and China, complemented by in-house manufacturing at Bayer and other large pharma firms. The supply chain features multiple vendors capable of high-standard GMP production, though geopolitical and quality concerns prompt diversification.

Key Takeaways

• Major API suppliers are located in India and China, with significant capacity.
• In-house production at Bayer maintains proprietary control.
• Quality standards and regulatory compliance are critical in sourcing API.
• Supply chain diversification mitigates geopolitical and logistical risks.
• Price range for vemurafenib API reflects complexity and purity standards.

Frequently Asked Questions

1. Which countries dominate the API supply for vemurafenib?

India and China are the primary sources, with some manufacturing at Bayer in Germany and other regions.

2. Are there alternative suppliers for vemurafenib API?

Yes, several contract manufacturers exist, though not all can meet scale or quality standards required.

3. What are common regulatory concerns for API sourcing?

Ensuring compliance with GMP, maintaining consistent purity, and verifying manufacturing certifications.

4. How does API price influence ZELBORAF manufacturing costs?

Higher purity and complex synthesis increase costs, with API prices directly impacting drug pricing.

5. Is in-house API manufacturing more reliable than outsourcing?

In-house manufacturing offers control over quality and supply but requires significant capital. Outsourcing offers scalability but introduces supply chain risks.

---

References

[1] U.S. Food and Drug Administration. (2022). Guidance for Industry: Quality Considerations in Demonstrating Biosimilarity to a Reference Product. FDA.gov.

[2] European Medicines Agency. (2021). API manufacturing standards and inspections. EMA.europa.eu.

[3] Market Research Future. (2022). API Market Overview: Trends, Growth, and Opportunities. MRFR.

[4] Pharmaceutical Technology. (2020). The supply chain challenges of sourcing APIs in China and India. PharmTech.com.

[5] World Health Organization. (2019). WHO Good Manufacturing Practices for Active Pharmaceutical Ingredients. WHO.int.